Clinical trial · Interventional
Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
Improving Oral Chemotherapy Adherence in Maintenance for Adolescents and Adults With Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Using Text Messages
NCT06446661CI-TRIAL-00117608recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single center 2-phase study to assess effects of using text messages on adherence to oral chemotherapy for patients with acute lymphoblastic leukemia (ALL) or T-cell lymphoblastic lymphoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | ONTOLOGY_EXACT | 0.98 |
| T-cell Lymphoblastic Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High Intensity | Other | — | UNRESOLVED |
| Low Intensity Text Messaging | Other | — | UNRESOLVED |
| No Text Messagings | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Efficacy Phase: High Intensity Messaging
- description
- Receives high-intensity text messaging for 2 cycles of treatment
- interventionNames
- Other: High Intensity
- type
- ACTIVE_COMPARATOR
- label
- Efficacy Phase: Low Intensity Messaging
- description
- Receives no texts for 1st cycle and low-intensity texts for 2nd cycle
- interventionNames
- Other: No Text Messagings
- Other: Low Intensity Text Messaging
- type
- EXPERIMENTAL
- label
- Pilot Phase Arm
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Age of 15 years or older at time of enrollment * Diagnosed with ALL or T-cell lymphoblastic lymphoma * Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance. Patients in the pilot phase may have already started maintenance as long as the end of their maintenance therapy is scheduled to occur after the end of the 28-day pilot intervention. Exclusion Criteria: * Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages * Patient does not wish to participate * Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.
References
Publications (0)
Data not yet available
No reference posted for this study.